Literature DB >> 32963118

Alphaherpesvirus Vaccines.

Clare Burn Aschner1, Betsy C Herold1.   

Abstract

Prophylactic and therapeutic vaccines for the alphaherpesviruses including varicella zoster virus (VZV) and herpes simplex virus types 1 and 2 have been the focus of enormous preclinical and clinical research. A live viral vaccine for prevention of chickenpox and a subunit therapeutic vaccine to prevent zoster are highly successful. In contrast, progress towards the development of effective prophylactic or therapeutic vaccines against HSV-1 and HSV-2 has met with limited success. This review provides an overview of the successes and failures, the different types of immune responses elicited by various vaccine modalities, and the need to reconsider the preclinical models and immune correlates of protection against HSV.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32963118      PMCID: PMC8211365          DOI: 10.21775/cimb.041.469

Source DB:  PubMed          Journal:  Curr Issues Mol Biol        ISSN: 1467-3037            Impact factor:   2.081


  148 in total

Review 1.  Novel adenovirus vector-based vaccines for HIV-1.

Authors:  Dan H Barouch
Journal:  Curr Opin HIV AIDS       Date:  2010-09       Impact factor: 4.283

Review 2.  Viruses as vaccine vectors for infectious diseases and cancer.

Authors:  Simon J Draper; Jonathan L Heeney
Journal:  Nat Rev Microbiol       Date:  2010-01       Impact factor: 60.633

3.  Antibodies to TR2 (herpesvirus entry mediator), a new member of the TNF receptor superfamily, block T cell proliferation, expression of activation markers, and production of cytokines.

Authors:  J A Harrop; M Reddy; K Dede; M Brigham-Burke; S Lyn; K B Tan; C Silverman; C Eichman; R DiPrinzio; J Spampanato; T Porter; S Holmes; P R Young; A Truneh
Journal:  J Immunol       Date:  1998-08-15       Impact factor: 5.422

4.  Stable binding of the herpes simplex virus ICP47 protein to the peptide binding site of TAP.

Authors:  R Tomazin; A B Hill; P Jugovic; I York; P van Endert; H L Ploegh; D W Andrews; D C Johnson
Journal:  EMBO J       Date:  1996-07-01       Impact factor: 11.598

Review 5.  Evolution and world-wide distribution of varicella-zoster virus clades.

Authors:  Jonas Schmidt-Chanasit; Andreas Sauerbrei
Journal:  Infect Genet Evol       Date:  2010-09-15       Impact factor: 3.342

6.  Protective vaccination against primary and recurrent disease caused by herpes simplex virus (HSV) type 2 using a genetically disabled HSV-1.

Authors:  C S McLean; M Erturk; R Jennings; D N Challanain; A C Minson; I Duncan; M E Boursnell; S C Inglis
Journal:  J Infect Dis       Date:  1994-11       Impact factor: 5.226

7.  Efficacy of the Herpes Zoster Subunit Vaccine in Adults 70 Years of Age or Older.

Authors:  Anthony L Cunningham; Himal Lal; Martina Kovac; Roman Chlibek; Shinn-Jang Hwang; Javier Díez-Domingo; Olivier Godeaux; Myron J Levin; Janet E McElhaney; Joan Puig-Barberà; Carline Vanden Abeele; Timo Vesikari; Daisuke Watanabe; Toufik Zahaf; Anitta Ahonen; Eugene Athan; Jose F Barba-Gomez; Laura Campora; Ferdinandus de Looze; H Jackson Downey; Wayne Ghesquiere; Iris Gorfinkel; Tiina Korhonen; Edward Leung; Shelly A McNeil; Lidia Oostvogels; Lars Rombo; Jan Smetana; Lily Weckx; Wilfred Yeo; Thomas C Heineman
Journal:  N Engl J Med       Date:  2016-09-15       Impact factor: 91.245

8.  Cytotoxicity against varicella zoster virus infected targets in children with acute leukemia.

Authors:  T Ihara; K Oitani; S Torigoe; K Kitamura; M Ito; H Kamiya; M Sakurai
Journal:  Acta Paediatr Jpn       Date:  1994-02

9.  Herpes simplex virus type 1 Fc receptor protects infected cells from antibody-dependent cellular cytotoxicity.

Authors:  G Dubin; E Socolof; I Frank; H M Friedman
Journal:  J Virol       Date:  1991-12       Impact factor: 5.103

10.  Protection from herpes simplex virus (HSV)-2 infection with replication-defective HSV-2 or glycoprotein D2 vaccines in HSV-1-seropositive and HSV-1-seronegative guinea pigs.

Authors:  Yo Hoshino; Lesley Pesnicak; Kennichi C Dowdell; Peter D Burbelo; David M Knipe; Stephen E Straus; Jeffrey I Cohen
Journal:  J Infect Dis       Date:  2009-10-01       Impact factor: 5.226

View more
  6 in total

1.  Realigning the LIGHT signaling network to control dysregulated inflammation.

Authors:  Carl F Ware; Michael Croft; Garry A Neil
Journal:  J Exp Med       Date:  2022-05-23       Impact factor: 17.579

Review 2.  Rational Design of Live-Attenuated Vaccines against Herpes Simplex Viruses.

Authors:  Brent A Stanfield; Konstantin G Kousoulas; Agustin Fernandez; Edward Gershburg
Journal:  Viruses       Date:  2021-08-18       Impact factor: 5.048

Review 3.  40 Years after the Registration of Acyclovir: Do We Need New Anti-Herpetic Drugs?

Authors:  Anna Majewska; Beata Mlynarczyk-Bonikowska
Journal:  Int J Mol Sci       Date:  2022-03-22       Impact factor: 5.923

4.  Efficacy of a gB + gD-based subunit vaccine and the adjuvant granulocyte-macrophage colony stimulating factor for pseudorabies virus in rabbits.

Authors:  Zhi Cao; Ke Zhang; Heng Zhang; Hongliang Zhang; Ying Yu; Dehua Yin; Hu Shan; Zhihua Qin
Journal:  Front Microbiol       Date:  2022-08-03       Impact factor: 6.064

5.  Antibodies Elicited in Response to a Single Cycle Glycoprotein D Deletion Viral Vaccine Candidate Bind C1q and Activate Complement Mediated Neutralization and Cytolysis.

Authors:  Maria Luisa Visciano; Aakash Mahant Mahant; Carl Pierce; Richard Hunte; Betsy C Herold
Journal:  Viruses       Date:  2021-06-30       Impact factor: 5.048

Review 6.  Local Immune Control of Latent Herpes Simplex Virus Type 1 in Ganglia of Mice and Man.

Authors:  Anthony J St Leger; David M Koelle; Paul R Kinchington; Georges Michel G M Verjans
Journal:  Front Immunol       Date:  2021-09-15       Impact factor: 8.786

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.